Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) loss in canine mammary carcinoma

Soo-Hyeon Kim1, Byung-Joon Seung1, Min-Kyung Bae1

  • 1Department of Veterinary Pathology, Small Animal Diagnostic Center, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea.

Insights

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) expression decreases in canine mammary tumors, impacting cancer progression. Downregulation of TRAIL and related molecules correlates with increased tumor grade.

Area of Science:

  • Oncology
  • Molecular Biology
  • Veterinary Pathology

Background:

  • Apoptosis evasion is a key cancer mechanism.
  • Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) regulates the extrinsic apoptotic pathway and is crucial in human oncology.
  • Endogenous TRAIL expression in canine tumors remains understudied.

Purpose of the Study:

  • To investigate endogenous TRAIL expression in canine mammary tumors.
  • To analyze TRAIL's correlation with downstream molecules (FADD, caspase-3) and the apoptotic index.
  • To understand TRAIL's role in canine mammary tumor progression.

Main Methods:

  • Immunohistochemistry performed on 147 canine mammary tissue samples (normal, adenoma, low-grade carcinoma, high-grade carcinoma).
  • RNA in situ hybridization and TUNEL assay conducted on 43 samples.
  • Analysis of TRAIL, FADD, and caspase-3 protein and mRNA expression, alongside apoptotic index.

Main Results:

  • TRAIL protein and mRNA expression significantly decreased in high-grade canine mammary carcinomas compared to normal glands and adenomas.
  • FADD and caspase-3 expression positively correlated with TRAIL expression.
  • Apoptotic index was paradoxically elevated in high-grade tumors despite reduced TRAIL.

Conclusions:

  • Loss of TRAIL expression is associated with malignant progression in canine mammary tumors.
  • Dysregulation of the TRAIL-induced extrinsic apoptotic pathway may contribute to canine mammary cancer development.
  • Findings highlight TRAIL's potential as a biomarker and therapeutic target in veterinary oncology.